1-(3,5-dimethoxyphenyl)-2-nitroethanol | 124471-31-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,5-dimethoxyphenyl)-2-nitroethanol
• 英文别名: 1-(3,5-Dimethoxyphenyl)-2-nitroethanol
• CAS: 124471-31-4
• 化学式: C₁₀H₁₃NO₅
• 分子量: 227.217
• InChiKey: AFCYCKCJJYWQJY-UHFFFAOYSA-N

物化性质

• 沸点：
  402.6±45.0 °C(Predicted)
• 密度：
  1.253±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  84.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(3,5-dimethoxyphenyl)-2-nitroethanol 在 盐酸 、 palladium on activated charcoal 、 氢气 、 N,N'-羰基二咪唑 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 15.0h， 生成 2-amino-N-(2-(3,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide hydrochloride
  参考文献：
  名称：

  신규한 α1-아드레날린 수용체 효능제

  摘要：

  This is the translation of the text you provided: This invention relates to a novel α1-adrenergic receptor agonist, more specifically to a novel analogue of midodrine, an α1-adrenergic receptor agonist. The midodrine analogue of this invention can be useful in the prevention and treatment of diseases requiring activation of AMPK (metabolic diseases, cardiovascular diseases, inflammatory diseases, etc.) by increasing the expression of key regulators of energy metabolism in the body, such as p-AMPK, PPARδ, and PGC-1α.

  公开号：

  KR20180065636A
• 作为产物：
  描述：

  硝基甲烷 、 3,5-二甲氧基苯甲醛 在 三乙胺 作用下， 以 乙醇 为溶剂， 生成 1-(3,5-dimethoxyphenyl)-2-nitroethanol
  参考文献：
  名称：

  氨基异冰片酚Schiff碱Cu2（SBAIB-d）2的铜配合物：直接催化不对称硝基吲哚（Henry）反应的高效催化剂

  摘要：

  为有效的直接催化不对称亨利反应，开发了一种新的氨基异冰片醇席夫碱双功能铜配合物Cu 2（SBAIB-d）2。一摩尔％的这种催化剂可产生高收率（高达99％ee）的预期亨利产物，并具有出色的对映选择性（高达98％ee）。本催化剂的实用性也扩展到了与硝基乙烷和1-硝基丙烷的亨利反应，从而以中等至高的收率（高达99％）提供了相应的产物，同时具有中等至高的对映体选择性的顺式（高达98％ee）和反（高达98％ee）非对映体。该催化体系的亮点是易于操作，耐空气和湿气，需要1摩尔％的易于合成的催化剂以及对多种底物都具有很高的对映选择性。

  DOI：

  10.1002/adsc.201200337

文献信息

• Copper Complex of Aminoisoborneol Schiff Base Cu ₂ (SBAIB‐d) ₂ : An Efficient Catalyst for Direct Catalytic Asymmetric Nitroaldol (Henry) Reaction
  作者：Ramalingam Boobalan、Gene‐Hsian Lee、Chinpiao Chen

  DOI：10.1002/adsc.201200337

  日期：2012.9.17

  new bifunctional copper complex of the aminoisoborneol Schiff base – Cu2(SBAIB‐d)2 – has been developed for the effective direct catalytic asymmetric Henry reaction. One mol% of this catalyst produces the expected Henry products in high yields (up to 99%) with excellent enantioselectivities (up to 98% ee). The utility of the present catalyst was also extended to the Henry reaction with nitroethane

  为有效的直接催化不对称亨利反应，开发了一种新的氨基异冰片醇席夫碱双功能铜配合物Cu 2（SBAIB-d）2。一摩尔％的这种催化剂可产生高收率（高达99％ee）的预期亨利产物，并具有出色的对映选择性（高达98％ee）。本催化剂的实用性也扩展到了与硝基乙烷和1-硝基丙烷的亨利反应，从而以中等至高的收率（高达99％）提供了相应的产物，同时具有中等至高的对映体选择性的顺式（高达98％ee）和反（高达98％ee）非对映体。该催化体系的亮点是易于操作，耐空气和湿气，需要1摩尔％的易于合成的催化剂以及对多种底物都具有很高的对映选择性。
• Highly efficient nanosized mesoporous CuMgAl ternary oxide catalyst
  申请人：King Abdulaziz University

  公开号：US11045792B1

  公开（公告）日：2021-06-29

  Highly efficient nanosized mesoporous CuMgAl ternary oxide catalysts are provided.

  提供高效的纳米级介孔CuMgAl三元氧化物催化剂。
• Hall, Robin J.; Shannon, Patrick V. R.; Oliveira-Campos, Ana M.-F., Journal of Chemical Research, Miniprint, 1992, # 1, p. 114 - 156
  作者：Hall, Robin J.、Shannon, Patrick V. R.、Oliveira-Campos, Ana M.-F.、Queiroz, Maria-Joao R. P.

  DOI：——

  日期：——
• Cyclen-catalyzed Henry reaction under neutral conditions
  作者：Chloé Vovard-Le Bray、Fan Jiang、Xiao-Feng Wu、Jean-Baptiste Sortais、Christophe Darcel

  DOI：10.1016/j.tetlet.2010.06.106

  日期：2010.8

  A convenient cyclen-catalyzed Henry reaction of aldehydes with nitroalkanes under mild and neutral conditions is reported. This procedure constitutes the first cyclen-catalyzed synthesis of nitroalcohols and is adapted to the condensation of both aromatic and aliphatic aldehydes with nitromethane in THF at room temperature without addition of stoichiometric amount of the base. A wide range of substrates, beta-nitroalcohols, were obtained in moderate to good yields (up to 98%) using this methodology. (C) 2010 Elsevier Ltd. All rights reserved.
• 신규한 α1-아드레날린 수용체 효능제
  申请人：Korea University Research and Business Foundation 고려대학교 산학협력단(220040170680) BRN ▼209-82-08298

  公开号：KR20180065636A

  公开（公告）日：2018-06-18

  본 발명은 신규한 α1-아드레날린 수용체 효능제에 관한 것으로, 보다 상세하게는 α1-아드레날린 수용체 효능제인 미도드린의 신규한 유사체에 관한 것이다. 본 발명의 미도드린 유사체는 생체내 에너지 대사활성 유지와 조절에 핵심적인 작용을 하는 p-AMPK, PPARδ, PGC-1α의 발현을 증가시킴으로써, AMPK의 활성화가 필요한 질환(대사질환, 심혈관질환, 염증질환 등)의 예방 및 치료에 유용하게 이용될 수 있다.

  This is the translation of the text you provided: This invention relates to a novel α1-adrenergic receptor agonist, more specifically to a novel analogue of midodrine, an α1-adrenergic receptor agonist. The midodrine analogue of this invention can be useful in the prevention and treatment of diseases requiring activation of AMPK (metabolic diseases, cardiovascular diseases, inflammatory diseases, etc.) by increasing the expression of key regulators of energy metabolism in the body, such as p-AMPK, PPARδ, and PGC-1α.